(CercleFinance.com) – The Goldman Sachs Group has declared to have indirectly crossed upwards, on December 20, 2021, the thresholds of 5% of the capital and the voting rights of the company Erytech Pharma and to hold, indirectly through the companies which it controls, 9.89% of the capital and 9.43% of the voting rights of this company.
This crossing of thresholds results from an acquisition of Erytech Pharma shares outside the market.